Senate Files

Bills

H.R. 4299 119th Congress

Protecting Patient Access to Cancer and Complex Therapies Act

Latest action, Jul 7, 2025: Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.

How the Senate voted

The Senate hasn't taken a roll call on this bill in the Congresses covered.

55 cosponsors

Sponsored by Rep. Murphy, Gregory F. [R-NC-3] (Republican). Cosponsors by party, House members included:

  • Democrats
  • Republicans
  • Independents
Cosponsors
17 D · 38 R

Referred to: House: Energy and Commerce Committee; House: Ways and Means Committee

Who lobbied on it

Clients whose quarterly lobbying reports named it, each quarter.

51 clientsQ2 2025Q3 2026

The clients with the most reports naming it. A report's amount covers all of that client's lobbying in the quarter, not just this bill.

INFUSION PROVIDERS ALLIANCE
THE MCMANUS GROUP
6 reports
INFUSION PROVIDERS ALLIANCE
6 reports
LARGE UROLOGY GROUP PRACTICE ASSOCIATION
THE MCMANUS GROUP
6 reports
LARGE UROLOGY GROUP PRACTICE ASSOCIATION (LUGPA)
AVENUE SOLUTIONS
6 reports
PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA
THE MCMANUS GROUP
6 reports
AMERICAN COLLEGE OF RHEUMATOLOGY
5 reports
ASSOCIATION FOR CLINICAL ONCOLOGY
5 reports
BRISTOL-MYERS SQUIBB COMPANY
5 reports
CARDINAL HEALTH INC
5 reports
COMMUNITY ONCOLOGY ALLIANCE
5 reports
DAIICHI SANKYO, INC.
TIBER CREEK GROUP
5 reports
GENENTECH
THE MCMANUS GROUP
5 reports
GENENTECH USA, INC.
AVENUE SOLUTIONS
5 reports
JOHNSON & JOHNSON SERVICES INC
5 reports
MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS (FORMER
NORTH SOUTH GOVERNMENT STRATEGIES, FKA JDM PUBLIC STRATEGIES, LLC
5 reports
All 25 of 53 clients
ClientLobbying firmReportsReports totalingFromToSenate
INFUSION PROVIDERS ALLIANCETHE MCMANUS GROUP6$0Q4 2025Q3 2026yes
INFUSION PROVIDERS ALLIANCE6$650KQ4 2025Q3 2026yes
LARGE UROLOGY GROUP PRACTICE ASSOCIATIONTHE MCMANUS GROUP6$540KQ4 2025Q3 2026yes
LARGE UROLOGY GROUP PRACTICE ASSOCIATION (LUGPA)AVENUE SOLUTIONS6$360KQ4 2025Q3 2026yes
PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICATHE MCMANUS GROUP6$0Q4 2025Q3 2026yes
AMERICAN COLLEGE OF RHEUMATOLOGY5$350KQ4 2025Q3 2026yes
ASSOCIATION FOR CLINICAL ONCOLOGY5$1.0MQ4 2025Q3 2026yes
BRISTOL-MYERS SQUIBB COMPANY5$12.0MQ4 2025Q3 2026yes
CARDINAL HEALTH INC5$3.3MQ4 2025Q3 2026yes
COMMUNITY ONCOLOGY ALLIANCE5$1.3MQ4 2025Q3 2026yes
DAIICHI SANKYO, INC.TIBER CREEK GROUP5$0Q4 2025Q3 2026yes
GENENTECHTHE MCMANUS GROUP5$0Q4 2025Q3 2026yes
GENENTECH USA, INC.AVENUE SOLUTIONS5$0Q4 2025Q3 2026yes
JOHNSON & JOHNSON SERVICES INC5$11.2MQ4 2025Q3 2026yes
MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS (FORMERNORTH SOUTH GOVERNMENT STRATEGIES, FKA JDM PUBLIC STRATEGIES, LLC5$150KQ4 2025Q3 2026yes
MCKESSON CORPORATION & ITS AFFILIATE U.S. ONCOLOGY5$3.7MQ4 2025Q3 2026yes
MERCK & CO., INCTIBER CREEK GROUP5$0Q4 2025Q3 2026yes
TAKEDA PHARMACEUTICALS AMERICA, INC.TIBER CREEK GROUP5$0Q4 2025Q3 2026yes
ABBVIE INC.4$5.6MQ4 2025Q3 2026yes
ASSOCIATION OF CANCER CARE CENTERS (FKA ASSOCIATION OF COMMUNITY CANCER CENTERS)4$40KQ4 2025Q3 2026yes
BRISTOL-MYERS SQUIBBTHE MCMANUS GROUP4$0Q4 2025Q3 2026yes
CENCORA, INC.4$4.0MQ4 2025Q3 2026yes
FERRING PHARMACEUTICALS, INC.4$1.0MQ4 2025Q3 2026yes
AMGEN INC3$8.2MQ1 2026Q3 2026yes
GILEAD SCIENCES, INC.THE MCMANUS GROUP3$0Q1 2026Q3 2026yes